Phillips, Lawrence D., Fasolo, Barbara ORCID: 0000-0002-4643-5689, Zafiropoulos, Nikolaos and Beyer, Andrea
(2011)
Is quantitative benefit–risk modelling of drugs desirable or possible?
Drug Discovery Today: Technologies, 8 (1).
e3-e10.
ISSN 1740-6749
Identification Number: 10.1016/j.ddtec.2011.03.001
Abstract
Preliminary research results with drug regulators in several European Agencies show that quantitative models developed with groups of assessors and specialists can integrate scientific data with expert value judgements, thereby extending the capabilities of regulators, and stimulating new insights about key trade-offs. As a result, the rationale for the benefit-risk balance becomes more transparent, communicable and consistent.
Item Type: | Article |
---|---|
Official URL: | http://www.journals.elsevier.com/drug-discovery-to... |
Additional Information: | © 2011 Elsevier |
Divisions: | Management |
Subjects: | R Medicine > RS Pharmacy and materia medica |
Date Deposited: | 24 Nov 2011 09:53 |
Last Modified: | 02 Jul 2024 07:57 |
URI: | http://eprints.lse.ac.uk/id/eprint/39733 |
Actions (login required)
![]() |
View Item |